Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Argatroban plus clopidogrel and aspirin for prevention of early neurological deterioration in acute penetrating artery infarction
ChiCTR2100046487Phase 4Recruiting
- Sponsor
- Chengdu Second People's Hospital
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of argatroban, clopidogrel and aspirin in ischemic stroke and lacunar infarct (2 arms), sponsored by Chengdu Second People's Hospital. Primary endpoints: Early neurological deterioration within 7 days and Good prognosis at 3 months. Started May 2021; status: recruiting.
02
Drugs
argatrobanclopidogrelaspirin
03
Conditions
ischemic strokelacunar infarct
Beyond the preview
Go deeper on ChiCTR2100046487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046487.